CN1299734C - 一种治疗大肠湿热证的中药组合物及其制备方法 - Google Patents
一种治疗大肠湿热证的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN1299734C CN1299734C CNB031499872A CN03149987A CN1299734C CN 1299734 C CN1299734 C CN 1299734C CN B031499872 A CNB031499872 A CN B031499872A CN 03149987 A CN03149987 A CN 03149987A CN 1299734 C CN1299734 C CN 1299734C
- Authority
- CN
- China
- Prior art keywords
- solution
- reference substance
- medicinal material
- chromatograph
- control medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 210000002429 large intestine Anatomy 0.000 title abstract description 11
- 201000010099 disease Diseases 0.000 title description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 41
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000004821 distillation Methods 0.000 claims abstract description 13
- 238000003908 quality control method Methods 0.000 claims abstract description 13
- 241000219784 Sophora Species 0.000 claims abstract 3
- 239000000243 solution Substances 0.000 claims description 198
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 138
- 238000012360 testing method Methods 0.000 claims description 108
- 239000013558 reference substance Substances 0.000 claims description 68
- 239000000463 material Substances 0.000 claims description 61
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 claims description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 54
- 208000011580 syndromic disease Diseases 0.000 claims description 41
- 210000000582 semen Anatomy 0.000 claims description 37
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 36
- 239000010282 Emodin Substances 0.000 claims description 36
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 36
- 241000628997 Flos Species 0.000 claims description 36
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 36
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 36
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 36
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 36
- 239000011259 mixed solution Substances 0.000 claims description 36
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 33
- 239000000047 product Substances 0.000 claims description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 32
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- 239000000741 silica gel Substances 0.000 claims description 24
- 229910002027 silica gel Inorganic materials 0.000 claims description 24
- 238000004809 thin layer chromatography Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 22
- 239000003208 petroleum Substances 0.000 claims description 18
- 238000010992 reflux Methods 0.000 claims description 16
- 239000007921 spray Substances 0.000 claims description 16
- 239000000796 flavoring agent Substances 0.000 claims description 15
- 235000019634 flavors Nutrition 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 claims description 12
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 229940039750 aconitine Drugs 0.000 claims description 12
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 230000003760 hair shine Effects 0.000 claims description 12
- IGWDEVSBEKYORK-UHFFFAOYSA-N isoimperatorin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)C IGWDEVSBEKYORK-UHFFFAOYSA-N 0.000 claims description 12
- 239000012567 medical material Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000341 volatile oil Substances 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000007689 inspection Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- ZPSAEGUNYMEKBP-UHFFFAOYSA-N 5-Isopentenyloxy-psoralen Natural products CC(C)C=COc1c2C=CC(=O)Oc2cc3occc13 ZPSAEGUNYMEKBP-UHFFFAOYSA-N 0.000 claims description 6
- BEYIWVKWKJROGZ-UHFFFAOYSA-N Alloimperatorin Natural products O1C(=O)C=CC2=C1C(O)=C1OC=CC1=C2OCC=C(C)C BEYIWVKWKJROGZ-UHFFFAOYSA-N 0.000 claims description 6
- KGGUASRIGLRPAX-UHFFFAOYSA-N Meranzin hydrate Natural products C1=CC(=O)OC2=C(CC(O)C(C)(C)O)C(OC)=CC=C21 KGGUASRIGLRPAX-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 claims description 6
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 238000001256 steam distillation Methods 0.000 claims description 6
- 238000011003 system suitability test Methods 0.000 claims description 6
- 239000012085 test solution Substances 0.000 claims description 6
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 6
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 6
- 235000012141 vanillin Nutrition 0.000 claims description 6
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- -1 drying Substances 0.000 claims description 4
- 238000012850 discrimination method Methods 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000009495 sugar coating Methods 0.000 claims description 2
- ODTFSOYNSMERHW-UHFFFAOYSA-N CCNCC.CCOC(C)=O.C1CCCCC1 Chemical compound CCNCC.CCOC(C)=O.C1CCCCC1 ODTFSOYNSMERHW-UHFFFAOYSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 238000004811 liquid chromatography Methods 0.000 claims 4
- 239000002994 raw material Substances 0.000 claims 3
- 241000245240 Lonicera Species 0.000 claims 2
- 208000021788 large intestine disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 60
- 206010012735 Diarrhoea Diseases 0.000 abstract description 49
- 208000001848 dysentery Diseases 0.000 abstract description 33
- 208000024891 symptom Diseases 0.000 abstract description 26
- 239000004615 ingredient Substances 0.000 abstract 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000080767 Areca catechu Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000008859 change Effects 0.000 description 22
- 210000002105 tongue Anatomy 0.000 description 19
- 206010000087 Abdominal pain upper Diseases 0.000 description 16
- 238000011084 recovery Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 206010057071 Rectal tenesmus Diseases 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 208000012271 tenesmus Diseases 0.000 description 8
- 206010028140 Mucous stools Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 206010006784 Burning sensation Diseases 0.000 description 6
- 206010013954 Dysphoria Diseases 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 210000000436 anus Anatomy 0.000 description 6
- 238000004820 blood count Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 235000019615 sensations Nutrition 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010030302 Oliguria Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101100276976 Drosophila melanogaster Drak gene Proteins 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000001142 anti-diarrhea Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229910021647 smectite Inorganic materials 0.000 description 4
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000000550 effect on aging Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000004915 pus Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 244000248539 Asparagus cochinchinensis Species 0.000 description 1
- 235000009292 Asparagus cochinchinensis Nutrition 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 239000009711 Huoxiang-zhengqi Substances 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 229940086239 acetaminophen 500 mg Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical group O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 102220106607 rs773955198 Human genes 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
组别 | 例数 | 男 | (%) | 女 | (%) | P |
治疗组对照组 | 200-70 | 11341 | (56.50)(58.57) | 8729 | (43.50)(41.43) | >0.05>0.05 |
组别 | 例数 | 男 | (%) | 女 | (%) | P |
治疗组对照组 | 10030 | 5917 | (59.00)(56.67) | 4113 | (41.00)(43.33) | >0.05>0.05 |
组别 | 例数 | 年龄分布(岁) | 平均年龄(岁) | P | |||||
18~30 | (%) | 31~50 | (%) | 51~65 | (%) | X±SD | |||
治疗组对照组 | 20070 | 9531 | (47.50)(44.29) | 7226 | (36.00)(37.14) | 3313 | (16.50)(18.57) | 35.55±18236.44±3.04 | >0.05>0.05 |
组别 | 例数 | 年龄分布(岁) | 平均年龄(岁) | P | |||||
18~30 | (%) | 31~50 | (%) | 51~65 | (%) | X±SD | |||
治疗组对照组 | 10030 | 5013 | (50.00)(43.33) | 3110 | (31.00)(33.33) | 197 | (19.00)(23.33) | 36.00±2.5537.00±4.50 | >0.05 |
组别 | 例数 | ≤3日 | 3日~1周 | >1周 |
例数(%) | 例数(%) | 例数(%) | ||
治疗组对照组 | 20070 | 124(62.00)37(52.86) | 61(30.5)26(37.14) | 15(%)7(10.00) |
组别 | 例数 | ≤3日 | 3日~1周 | >1周 |
例数(%) | 例数(%) | 例数(%) | ||
治疗组对照组 | 10030 | 68(68.00)16(53.33) | 24(24.00)9(30.00) | 8(8.00)5(16.67) |
症状 | 治疗组 | (%) | 对照组 | (%) | P |
泄泻急迫泄而不爽里急后重***灼热腹痛烦热口渴小便短赤大便黄褐而臭下痢赤白粘液便稀水便 | 491481931672001741632618019222 | (24.50)(74.00)(96.50)(83.50)(100.00)(87.00)(81.50)(13.00)(90.00)(96.00)(11.00) | 145367637060561061677 | (20.00)(75.71)(95.71)(90.00)(100.00)(85.71)(80.00)(14.29)(87.14)(95.71)(10.00) | >0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05 |
症状 | 治疗组 | (%) | 对照组 | (%) | P |
泄泻急迫泄而不爽里急后重***灼热腹痛烦热口渴小便短赤大便黄褐而臭下痢赤白粘液便稀水便 | 85862881009165590041 | (85.00)(86.00)(2.00)(88.00)(100.00)(91.00)(65.00)(59.00)(0)(0)(41.00) | 242602830241621009 | (80.00)(86.67)(0)(93.33)(100.00)(80.00)(53.33)(70.00)(0)(0)(30.00) | >0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05 |
组别 | 例数 | 舌象 | 例数 | 脉象 | P | ||
异常 | 正常 | 异常 | 正常 | ||||
治疗组对照组 | 20070 | 19467 | 63 | 20070 | 20070 | 00 | >0.05>0.05 |
组别 | 例数 | 舌象 | 例数 | 脉象 | P | ||
异常 | 正常 | 异常 | 正常 | ||||
治疗组对照组 | 10030 | 9028 | 102 | 10030 | 10030 | 00 | >0.05>0.05 |
项目 | 例数 | 治疗组 | 例数 | 对照组 | P | ||
异常 | 正常 | 异常 | 正常 | ||||
白细胞分类计数大便常规 | 200200 | 75200 | 1250 | 7070 | 22070 | 480 | >0.05>0.05 |
项目 | 例数 | 治疗组 | 例数 | 对照组 | P | ||
异常 | 正常 | 异常 | 正常 | ||||
白细胞分类计数大便常规 | 100100 | 29100 | 710 | 3030 | 1030 | 200 | >0.05>0.05 |
组别 | 例数 | 临床痊愈(%) | 显效(%) | 有效(%) | 无效(%) | 总有效率(%) |
治疗组对照组 | 20070 | 80(40.00)18(25.71) | 47(23.50)22(31.43) | 52(26.00)20(28.57) | 21(10.50)10(14.29) | (89.50)(85.71) |
组别 | 例数 | 临床痊愈(%) | 显效(%) | 有效(%) | 无效(%) | 总有效率(%) |
治疗组对照组 | 12030 | 33(33.00)6(20.00) | 31(31.00)9(30.00) | 28(28.00)7(23.33) | 8(8.000)8(26.67) | (92.00)(73.33) |
病程 | 例数 | 治疗组 | 总有效率(%) | 例数 | 对照组 | 总有效率(%) | ||||||
临床痊愈 | 显效 | 有效 | 无效 | 临床痊愈 | 显效 | 有效 | 无效 | |||||
≤3日3日~1周>1周 | 1246115 | 49265 | 30125 | 34162 | 1173 | (91.13)(88.52)(80.00) | 37267 | 1071 | 1282 | 1082 | 532 | (86.49)(88.46)(71.43) |
病程 | 例数 | 治疗组 | 总有效率(%) | 例数 | 对照组 | 总有效率(%) | ||||||
临床痊愈 | 显效 | 有效 | 无效 | 临床痊愈 | 显效 | 有效 | 无效 | |||||
≤3日3日~1周>1周 | 68248 | 22101 | 2452 | 1873 | 422 | (94.12)(91.67(75.00) | 1695 | 411 | 531 | 322 | 431 | (75.00)(66.67)(80.00) |
症状 | 例数 | 治疗组 | 总有效率(%) | 例数 | 对照组 | 总有效率(%) | P | ||||||
消失 | 显效 | 有效 | 无效 | 消失 | 显效 | 有效 | 无效 | ||||||
泄泻急迫泄而不爽里急后重***灼热腹痛烦热口渴小便短赤大便黄褐而臭下痢赤白粘液便稀水便 | 491481931672001741632618019222 | 2441101431183633576897 | 14504542573637960536 | 6433063176268737397 | 514171981402557112 | (89.80)(90.54)(91.19)(88.62)(96.00)(77.01)(84.66)(80.77)(96.11)(94.27)(90.91) | 145367637060561061677 | 5142624161719419202 | 2132014181715317152 | 4141117241511114221 | 312108121111211102 | (78.57)(77.36)(85.07)(87.30)(82.86)(81.67)(80.36)(80.00)(81.97)(85.17)(71.43) | >0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05>0.05 |
症状 | 例数 | 治疗组 | 总有效率(%) | 例数 | 对照组 | 总有效率(%) | P | ||||||
消失 | 显效 | 有效 | 无效 | 消失 | 显效 | 有效 | 无效 | ||||||
泄泻急迫泄而不爽里急后重***灼热腹痛烦热口渴小便短赤大便黄褐而臭下痢赤白粘液便稀水便 | 85862881009165590041 | 3133032512413130012 | 1917033173021310017 | 2730115282922120010 | 86184893002 | (90.59)(93.02)(50.00)(90.91)(96.00)(91.21)(86.15)(94.92)(0)(0)(95.12) | 2426028302401621009 | 456065323002 | 6901071027003 | 34078643002 | 1170510588002 | (54.17)(73.08)(0)(82.14)(66.67)(79.17)(50.00)(61.90)(0)(0)(77.78) | <0.05>0.05>0.05>0.05<0.05>0.05<0.05<0.05>0.05>0.05>0.05 |
组别 | 舌象 | 脉象 | ||||
疗前异常 | 疗前改善(%) | 疗后转常(%) | 疗前异常 | 疗前改善(%) | 疗后转常(%) | |
治疗组对照组 | 19467 | 89(45.88)25(37.31) | 48(24.74)15(22.39) | 20017 | 69(34.50)17(24.29) | 43(21.50)12(17.14) |
组别 | 舌象 | 脉象 | ||||
疗前异常 | 疗前改善(%) | 疗后转常(%) | 疗前异常 | 疗前改善(%) | 疗后转常(%) | |
治疗组对照组 | 19467 | 89(45.88)25(37.31) | 48(24.74)15(22.39) | 20017 | 69(34.50)17(24.29) | 43(21.50)12(17.14) |
组别 | 舌象 | 脉象 | ||||
疗前异常 | 疗前改善(%) | 疗后转常(%) | 疗前异常 | 疗前改善(%) | 疗后转常(%) | |
治疗组对照组 | 7522 | 33(44.00)9(40.91) | 25(33.33)15(27.27) | 20070 | 92(46.00)29(41.43) | 94(47.00)20(28.57) |
组别 | 舌象 | 脉象 | ||||
疗前异常 | 疗前改善(%) | 疗后转常(%) | 疗前异常 | 疗前改善(%) | 疗后转常(%) | |
治疗组对照组 | 2967 | 89(45.88)25(37.31) | 48(24.74)15(22.39) | 20017 | 69(34.50)17(24.29) | 43(21.50)12(17.14) |
年龄(岁) | 例数 | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) | P |
18~3031~5051~65 | 957233 | 432413 | 20207 | 22219 | 1074 | 89.4790.2887.88 | >0.05 |
年龄(岁) | 例数 | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) | P |
18~3031~5051~65 | 503119 | 2076 | 15115 | 13105 | 233 | 96.0090.3284.21 | >0.05 |
疾病 | 例数 | 痊愈 | 显效 | 有效 | 无效 | 总有效率(%) |
泄泻痢疾 | 100200 | 3380 | 3147 | 2852 | 821 | (92.00)(89.50) |
组别 | 剂量(g/kg) | 大鼠皮下注射干酵母后的体温升幅(℃) | |||||
1h | 2h | 3h | 4h | 5h | 6h | ||
空白组模型组对乙酰氨基酚组湿热片组 | --0.250.3620.7231.45 | 0.28±0.120.33±0.140.24±0.110.31±0.170.32±0.160.22±0.13 | 0.32±0.06*0.45±0.150.29±0.10*0.44±0.080.39±0.150.33±0.14 | 0.40±0.10**0.91±0.380.40±0.21**0.94±0.230.57±0.27*0.55±0.18* | 0.54±0.19*0.74±0.160.27±0.09**0.61±0.220.60±0.170.44±0.12** | 0.34±0.11**1.90±0.330.58±0.13**1.58±0.581.52±0.481.26±0.28** | 0.33±0.12**2.20±0.420.41±0.13**1.89±0.411.88±0.311.37±0.34** |
组别 | 剂量(g/kg) | 小鼠累积腹泻次数(次) | |||
1h | 2h | 3h | 4h | ||
空白组模型组思密达组湿热片组 | --2.00.3620.7231.45 | 5.20±1.817.40±4.674.30±2.364.60±1.265.30±1.644.80±2.62 | 8.90±1.97**25.40±7.7512.40±2.17**22.10±4.0118.70±2.45*14.60±4.38** | 14.10±4.04**33.20±7.2117.70±3.74**29.2±8.3626.60±4.40*19.50±3.89** | 16.00±4.32**36.00±6.8219.30±4.00**32.60±8.7828.5±6.38*21.60±5.36** |
组别 | 剂量(g/kg) | 小鼠疼痛扭体的次数(次) |
空白组阿司匹林组热湿片组 | -0.010.3620.7231.45 | 12.90±4.934.70±1.57**10.90±2.968.20±2.53*6.70±1.83** |
菌种 | 湿热片浓度(g/kg) | 阴性对照 | 阳性对照 | ||||
0.2 | 0.1 | 0.05 | 0.025 | 0.0125 | |||
大肠杆菌(44102)绿脓杆菌(10104)沙门氏菌(50094)金葡菌(26003)白色念珠菌(98001) | ----- | ++--- | ++++- | +++++ | +++++ | ----- | +++++ |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031499872A CN1299734C (zh) | 2003-08-01 | 2003-08-01 | 一种治疗大肠湿热证的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031499872A CN1299734C (zh) | 2003-08-01 | 2003-08-01 | 一种治疗大肠湿热证的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1579455A CN1579455A (zh) | 2005-02-16 |
CN1299734C true CN1299734C (zh) | 2007-02-14 |
Family
ID=34579746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031499872A Expired - Lifetime CN1299734C (zh) | 2003-08-01 | 2003-08-01 | 一种治疗大肠湿热证的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1299734C (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199776B (zh) * | 2007-12-13 | 2011-03-23 | 骆金根 | 一种治疗湿热型泄泻的浸泡药物 |
US8489539B2 (en) * | 2009-10-05 | 2013-07-16 | Elc Management, Llc | Computer-aided diagnostic systems and methods for determining skin compositions based on traditional chinese medicinal (TCM) principles |
CN102590434B (zh) * | 2012-03-01 | 2014-08-13 | 西藏奇正藏药股份有限公司 | 八味安宁制剂的检测方法 |
CN103801107B (zh) * | 2012-11-15 | 2017-03-01 | 上海家化联合股份有限公司 | 一种具有抗白色念珠菌作用的中药挥发油 |
CN106198833A (zh) * | 2016-06-24 | 2016-12-07 | 广西灵峰药业有限公司 | 一种明泽胶囊的生产质量控制方法 |
CN106491937A (zh) * | 2016-12-25 | 2017-03-15 | 闫大伟 | 一种治疗大肠湿热证的中药 |
CN108956844B (zh) * | 2018-07-27 | 2020-09-11 | 河北中医学院 | 一种养胃汤冻干粉多味药材多信息快速薄层鉴别方法 |
-
2003
- 2003-08-01 CN CNB031499872A patent/CN1299734C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1579455A (zh) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100346819C (zh) | 一种治疗***疾病的中药制剂及其生产方法 | |
CN1682936A (zh) | 一种治疗高血脂症的药物组合物及其制备方法 | |
CN101040915A (zh) | 一种双黄连注射液的制备方法及其成分检测方法 | |
CN1212134C (zh) | 一种治疗泌尿***感染和***炎的中药复方制剂 | |
CN1565552A (zh) | 治疗免疫功能低下或紊乱的中药 | |
CN1299734C (zh) | 一种治疗大肠湿热证的中药组合物及其制备方法 | |
CN1698878A (zh) | 一种补肾的药物组合物及其制备方法和新用途 | |
CN1813819A (zh) | 猴头子实体或猴头菌丝体及培养物提取物及制剂和制法 | |
CN1203872C (zh) | 一种治疗慢性结肠炎的药物 | |
CN1248718C (zh) | 治疗支原体肺炎的药物组合物及其制备和质量控制方法 | |
CN1692933A (zh) | 治疗乳腺增生的中药复方制剂及其制备方法 | |
CN1899325A (zh) | 一种治疗小儿腹泻的颗粒剂 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1745788A (zh) | 一种治疗小儿腹泻的中药制剂及制备方法 | |
CN1548138A (zh) | 一种治疗虚损病的中药组合物及其质量控制方法 | |
CN1814221A (zh) | 一种治疗***的中药组合物及其制备方法 | |
CN1528391A (zh) | 三子汤新制剂及其制备 | |
CN1197612C (zh) | 治疗泌尿***结石和***疾病的中药制剂及其制备方法 | |
CN100337658C (zh) | 治疗感冒风热症的中药组合物及其制备方法 | |
CN1237995C (zh) | 能够使异常黑胆质型体液成熟和清除的药物及其制备方法 | |
CN101057952A (zh) | 一种治疗痛经的药物组合物及其制备方法和应用 | |
CN1679692A (zh) | 一种治疗淋病的药物及其制备方法 | |
CN1148217C (zh) | 治疗慢性支气管炎的中成药 | |
CN105920083A (zh) | 玉屏风散在提高免疫力中的应用 | |
CN1742845A (zh) | 一种治疗呼吸***疾患的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG LIANKANG MEDICINE CO., LTD. Free format text: FORMER OWNER: ZHANG JIANLI Effective date: 20091113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091113 Address after: Xingning City, Guangdong province Zhen town walled zip code: 514500 Patentee after: GUANGDONG LIANKANG PHARMACEUTICAL Co.,Ltd. Address before: Guangdong city of Xingning province Xing Ye Lu, Guangdong Mingzhu Pharmaceutical Co. Ltd. postcode: 514500 Co-patentee before: Chen Junyao Patentee before: Zhang Jianli |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230717 Address after: 415699 Anxiang County Industrial Park, Changde City, Hunan Province Patentee after: Jiangyou Pharmaceutical (Changde) Co.,Ltd. Address before: 514500 Mizhai, Xingcheng Town, Xingning City, Guangdong Province Patentee before: GUANGDONG LIANKANG PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070214 |
|
CX01 | Expiry of patent term |